CLAIMS

1. A quinoline derivative of the Formula I



I

wherein Z^1 is an O, S, SO, SO_2, $N(R^2)$ or $C(R^2)_2$ group, wherein each R^2 group, which may be the same or different, is hydrogen or (1-6C)alkyl;

m is 0, 1, 2, 3 or 4;

each R^1 group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$Q^1\text{-}X^1\text{-}$$

wherein X^1 is a direct bond or is selected from O, S, SO, SO_2, $N(R^4)$, CO, $CH(OR^4)$, $CON(R^4)$, $N(R^4)CO$, $SO_2N(R^4)$, $N(R^4)SO_2$, $OC(R^4)_2$, $SC(R^4)_2$ and $N(R^4)C(R^4)_2$, wherein R^4 is hydrogen or (1-6C)alkyl, and Q^1 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or $(R^1)_m$ is (1-3C)alkylenedioxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO_2,

$N(R^5)$, CO, $CH(OR^5)$, $CON(R^5)$, $N(R^5)CO$, $SO_2N(R^5)$, $N(R^5)SO_2$, CH=CH and C≡C wherein R^5 is hydrogen or (1-6C)alkyl or, when the inserted group is $N(R^5)$, R^5 may also be (2-6C)alkanoyl,

and wherein any CH_2=CH- or HC≡C- group within a R^1 substituent optionally bears at the terminal CH_2= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :

$$Q^2-X^2-$$

wherein X^2 is a direct bond or is selected from CO and $N(R^6)CO$, wherein R^6 is hydrogen or (1-6C)alkyl, and Q^2 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH, CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^3-Q^3$$

wherein X^3 is a direct bond or is selected from O, S, SO, SO_2, $N(R^7)$, CO, $CH(OR^7)$, $CON(R^7)$, $N(R^7)CO$, $SO_2N(R^7)$, $N(R^7)SO_2$, $C(R^7)_2O$, $C(R^7)_2S$ and $N(R^7)C(R^7)_2$, wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,

di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^4-R^8$$

wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula :

$$-X^5-Q^4$$

wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo or thioxo substituents;

n is 0, 1, 2 or 3;

each R^3 group is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^6-R^{11}$$

wherein X^6 is a direct bond or is selected from O and $N(R^{12})$, wherein R^{12} is hydrogen or (1-6C)alkyl, and R^{11} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl;

Z^2 is a C≡C or $C(R^{13})=C(R^{13})$ group, wherein each R^{13} group, which may be the same or different, is hydrogen or (1-6C)alkyl; and

R^{14} is selected from halogeno, cyano, isocyano, formyl, carboxy, carbamoyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond or is selected from CO, $CH(OR^{15})$, $CON(R^{15})$ or $SO_2N(R^{15})$, wherein R^{15} is hydrogen or (1-6C)alkyl, and Q^5 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or is selected from O, S, SO, SO_2, $N(R^{16})$, CO, $CH(OR^{16})$, $CON(R^{16})$, $N(R^{16})CO$, $SO_2N(R^{16})$, $N(R^{16})SO_2$, $C(R^{16})_2O$, $C(R^{16})_2S$ and $N(R^{16})C(R^{16})_2$, wherein R^{16} is hydrogen or (1-6C)alkyl, and Q^6 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^9-R^{17}$$

wherein X^9 is a direct bond or is selected from O and $N(R^{18})$, wherein R^{18} is hydrogen or (1-6C)alkyl, and R^{17} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula :

$$-X^{10}-Q^7$$

wherein X^{10} is a direct bond or is selected from O, $N(R^{19})$ and CO, wherein R^{19} is hydrogen or (1-6C)alkyl, and Q^7 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo or thioxo substituents;

or a pharmaceutically-acceptable salt thereof.

2. A quinoline derivative of the Formula I or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R^1, R^2, R^3, Z^1, Z^2, m and n have any of the meanings defined in claim 1 and

R^{14} is selected from halogeno, cyano, formyl, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond or CO and Q^5 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino or from a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or is selected from O, $N(R^{16})$, $CON(R^{16})$, $N(R^{16})CO$ and $C(R^{16})_2O$, wherein R^{16} is hydrogen or (1-6C)alkyl, and Q^6 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected from a group of the formula :

$$-X^9-R^{17}$$

wherein X^9 is a direct bond or is selected from O and $N(R^{18})$, wherein R^{18} is hydrogen or (1-6C)alkyl, and R^{17} is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula :

$$-X^{10}-Q^7$$

wherein X^{10} is a direct bond or is selected from O, $N(R^{19})$ and CO, wherein R^{19} is hydrogen or (1-6C)alkyl, and Q^7 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2

substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo substituents;

3. A quinoline derivative of the Formula I according to claim 1wherein :

Z^1 is O or NH;

m is 1 and the R^1 group is located at the 5-, 6- or 7-position or m is 2 and each R^1 group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R^1 is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, 2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy, 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy and 3-homopiperazin-1-ylpropoxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH=CH and C≡C,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diethylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino and acetoxy;

and wherein any heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro,

trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, N-methylcarbamoyl and N,N-dimethylcarbamoyl and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R^1 substituent is optionally N-substituted with allyl, methylsulphonyl, acetyl, 2-fluoroethyl, 3-fluoropropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

n is 0 or 1 and the R^3 group, if present, is located at the 5- or 6-position of the benzofuran-7-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, ethynyl, methoxy and ethoxy;

Z^2 is a C≡C or CH=CH group; and

R^{14} is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N,N-diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, methylaminomethyl, ethylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, 2-acetamidoethyl and 3-acetamidopropyl, or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond or CO and Q^5 is 1-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, 1-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1-homopiperidinylmethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl or 3-morpholinopropyl,

and wherein any CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro, chloro or methyl groups or a substituent selected from hydroxy, amino, methoxy, methylamino, dimethylamino, acetoxy, acetamido and N-methylacetamido,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :

$$-X^9-R^{17}$$

wherein X^9 is a direct bond and R^{17} is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo substituents;

or a pharmaceutically-acceptable acid-addition salt thereof.

4. A quinoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R^1, R^2, R^3, R^{14}, Z^2, m and n have any of the meanings defined in claim 1 and Z^1 is NH.

5. A quinoline derivative of the Formula I according to claim 1 wherein :

Z^1 is NH;

m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,

2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy, 2-(2-pyrrolidin-1-ylethoxy)ethoxy, 2-(2-morpholinoethoxy)ethoxy, 2-(2-piperidinoethoxy)ethoxy and 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy;

n is 0 or n is 1 and the R^3 group, if present, is located at the 5- position of the benzofuran-7-yl group and is selected from chloro and bromo;

the $-Z^2-R^{14}$ group is located at the 4-position on the benzofuran-7-yl group,

Z^2 is a C≡C or CH=CH group; and

R^{14} is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-(2-methoxyethyl)carbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-(2-methoxyethyl)-N-methylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl and 3-morpholinopropyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

6. A quinoline derivative of the Formula I according to claim 1 wherein :

Z^1 is NH;

m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy,

2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy and 2-(2-pyrrolidin-1-ylethoxy)ethoxy;

n is 0 or n is 1 and R^3 is a chloro group located at the 5-position of the benzofuran-7-yl group;

the $-Z^2-R^{14}$ group is located at the 4-position on the benzofuran-7-yl group,

Z^2 is a C≡C group; and

R^{14} is selected from hydroxymethyl, methoxymethyl, dimethylaminomethyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl and piperazin-1-ylmethyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

7. A quinoline derivative of the Formula I according to claim 1 wherein :

Z^1 is NH;

m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy and 2-(2-pyrrolidin-1-ylethoxy)ethoxy;

n is 0 or n is 1 and R^3 is a chloro group located at the 5-position of the 1,3-benziodioxol-4-yl group;

the $-Z^2-R^{14}$ group is located at the 4-position on the benzofuran-7-yl group,

Z^2 is a CH=CH group; and

R^{14} is selected from cyano, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-(2-methoxyethyl)carbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-(2-methoxyethyl)-N-methylcarbamoyl, acetyl, propionyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylcarbonyl, piperidinocarbonyl and piperazin-1-ylcarbonyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

8. A process for the preparation of a quinoline derivative of the Formula I or a pharmaceutically-acceptable salt thereof, according to claim 1 which comprises:-

(a) the reaction of a quinoline of the Formula II



II

wherein L is a displaceable group and m and R^1 have any of the meanings defined in claim 1 hereinbefore except that any functional group is protected if necessary, with a compound of the Formula III



III

wherein Z^1 is O, S, or N(R^2) and n, R^3, R^2, Z^2 and R^{14} have any of the meanings defined in claim1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(b) for the production of those compounds of the Formula I wherein at least one R^1 group is a group of the formula

Q^1-X^1-

wherein Q^1 is an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group or an optionally substituted alkyl group and X^1 is an oxygen atom, the coupling, conveniently in the presence of a suitable dehydrating agent, of a quinoline of the Formula V



V

wherein m, R^1, Z^1, n, R^3, Z^2 and R^{14} have any of the meanings defined in claim 1, except that any functional group is protected if necessary, with an appropriate alcohol of the formula Q^1-OH wherein any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(c) for the production of those compounds of the Formula I wherein R^1 is an amino-substituted (1-6C)alkoxy group (such as 2-homopiperidin-1-ylethoxy or 3-dimethylaminopropoxy), the reaction of a compound of the Formula I wherein R^1 is a halogeno-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine;

(d) for the production of those compounds of the Formula I wherein an R^1 group contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation of a quinoline derivative of the Formula I wherein the R^1 group contains a hydroxy group or a primary or secondary amino group as appropriate;

(e) for the production of those compounds of the Formula I wherein Z^1 is a SO or SO_2 group, wherein an R^1 or R^3 substituent is a (1-6C)alkylsulphinyl or (1-6C)alkylsulphonyl group or wherein an R^1, R^3 or R^{14} substituent contains a SO or SO_2 group, the oxidation of a compound of the Formula I wherein Z^1 is a S group or wherein an R^1 or R^3 substituent is a (1-6C)alkylthio group or wherein an R^1, R^3 or R^{14} substituent contains a S group as appropriate;

(f) the reaction of a compound of the Formula VI



VI

wherein L is a displaceable group and m, R^1, Z^1, n and R^3 have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with a compound of the Formula VII

$$HZ^2—R^{14}$$ VII

wherein Z^2 is a C≡C or $C(R^{13})=C(R^{13})$ group and R^{13} and R^{14} have any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(g) for the production of a compound of the Formula I wherein R^{14} is a carboxy group, the cleavage of a compound of the Formula I wherein R^{14} is a (1-6C)alkoxycarbonyl group;

(h) the reaction of a compound of the Formula I wherein R^{14} is a carboxy group with an appropriate amine to form a further compound of the Formula I wherein R^{14} is a carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl or heterocyclylcarbonylamino group; or

(i) a coupling reaction of a compound of the Formula VIII



VIII

wherein m, R^1, Z^1, n and R^3 have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with a compound of the Formula IX

$$L—R^{14} \qquad IX$$

wherein L is a displaceable group and R^{14} has any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

and when a pharmaceutically-acceptable salt of a quinoline derivative of Formula I is required it may be obtained using a conventional procedure.

9. A pharmaceutical composition which comprises a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

10. A quinoline derivative of the Formula I or a pharmaceutically acceptable salt thereof for use in a method of the treatment of the human or animal body by therapy.

11. A quinoline derivative of the Formula I or a pharmaceutically acceptable salt thereof, as defined in claim1 for use in the treatment of cancer.

12. The use of a quinoline derivative of the Formula I or a pharmaceutically acceptable salt thereof as defined in claim 1 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

13. The use of a quinoline derivative of the Formula I or a pharmaceutically acceptable salt thereof as defined in claim 1 in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.